National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2012 (No. 1) (No. PB 8 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L00437

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
PB 8 of 2012
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2012 (No.1)
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated  27   February 2012
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1          Name of Instrument
            (1)        This Instrument is the National Health (Growth Hormone Program)
                        Special Arrangement Amendment Instrument 2012 (No.1).
            (2)        This Instrument may also be cited as PB 8 of 2012.
2          Commencement
(1)       Sections 1 to 3 and Schedule 1 are taken to have commenced on
           1 December 2011.
(2)       Schedule 2 commences on 1 March 2012.
3          Amendment of PB 88 of 2011
            Schedules 1 and 2 amend the National Health (Growth Hormone Program) Special Arrangement 2011 (PB 88 of 2011).
 
 
 
 
 
Schedule 1     Amendments
 
[1]           Subsection 47(2),
substitute:
 
(2)   However, if the form of the pharmaceutical benefit and the manufacturer’s pack is unable to accommodate the dose level mentioned
              in the item of the table that applies to a person, the dose of pharmaceutical benefit that the Secretary determines:
 
(a)    for a person eligible for the maximum dose level of an item of the table – may be within 3% of the maximum dose level of the item of the table that applies to the person; or
(b)   for any other person – may be the closest available dose to a dose level mentioned in the table that applies to the person.
 
(2A) If paragraph (2)(a) or (b) applies, the dose determined by the Secretary is taken to be the dose level mentioned in the item.
 
 
 
 
 
 
 
 
 
Schedule 2     Amendments
 
[1]        Schedule 1, after
 
 
Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)
Injection
Humatrope
LY
AMP
D
insert:
 
Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative)
Injection
Saizen
SG
AMP
D
 
[2]           Schedule 1, after
 
 
Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative)
Injection
Genotropin GoQuick
PF
AMP
D
insert:
 
Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Saizen
SG
AMP
D
 
[3]           Schedule 1, after
 
 
Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin NordiFlex
NO
AMP
D

 
 
 
Norditropin FlexPro
NO
AMP
D

 
 
 
Norditropin SimpleXx
NO
AMP
D

insert:
 
Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative)
Injection
Saizen
SG
AMP
D
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the
Legislative Instruments Act 2003.  See http://www.frli.gov.au.